Is zanidatamab better than trastuzumab in HER2 IHC 2+?

<p>Thoughts on the HER2 3+ and HER2 2+/ISH+ subgroups for zanidatamab, and its mechanism of action</p><p><br></p><p>JACOB trial: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30481-9/abstract</p><p><br></p><p>INNOVATION trial: https://ascopubs.org/doi/10.1200/JCO.2025.43.4_suppl.LBA331</p><p><br></p><p>HERIZON-GEA-01: https://www.nejm.org/doi/full/10.1056/NEJMoa2517729</p><p><br></p><p>Zanidatamab preclinical study: <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10011572/">https://pmc.ncbi.nlm.nih.gov/articles/PMC10011572/</a>N</p>